Mesoporous silicon particles for sustained gene silencing

Methods in Molecular Biology

Volumn 1049, Issue , 2013, Pages 481-493

  Hasan, Nafis ^a   Mann, Aman ^b   Ferrari, Mauro ^c   Tanaka, Takemi ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b BURNHAM INSTITUTE   (United States)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

Liposome; Mesoporous silicon particle; Multistage delivery; Nanoparticle; Ovarian cancer; RNA interference; Small interfering RNA; Sustained gene silencing

Indexed keywords

EPHRIN RECEPTOR A2; LIPOSOME; NANOPARTICLE; ONCOPROTEIN; SILICON; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GENE SILENCING; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; TUMOR GROWTH; ANIMAL; GENE THERAPY; GENE TRANSFER; GENETICS; HUMAN; OVARIAN NEOPLASMS; PATHOLOGY; PROCEDURES; RNA INTERFERENCE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; FEMALE; GENE SILENCING; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; LIPOSOMES; MICE; NANOPARTICLES; OVARIAN NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SILICON;

EID: 84881592682     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-547-7_36     Document Type: Article

References (21)

1. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464(7291):173-184
2. Kim DH, Rossi JJ (2007) Strategies for silencing human disease using RNA interference. Nat Rev Genet 8(3):173-184
3. Check E (2005) A crucial test. Nat Med 11(3):243-244
4. DeVincenzo JP (2008) RNA interference strategies as therapy for respiratory viral infections. Pediatr Infect Dis J 27(10 Suppl):S118-S122
5. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10(8):789-799
6. Rugo HS (2004) Bevacizumab in the treatment of breast cancer: Rationale and current data. Oncologist 9(Suppl 1):43-49
7. Tripathy D (2005) Targeted therapies in breast cancer. Breast J 11(Suppl 1):S30-S35
8. Bumcrot D, Manoharan M, Koteliansky V, Sah DW (2006) RNAi therapeutics: A potential new class of pharmaceutical drugs. Nat Chem Biol 2(12):711-719
9. Aagaard L, Rossi JJ (2007) RNAi therapeutics: Principles, prospects and challenges. Adv Drug Deliv Rev 59(2-3):75-86
10. Heidel JD, Yu Z, Liu JY, Rele SM, Liang Y, Zeidan RK, Kornbrust DJ, Davis ME (2007) Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA 104(14):5715-5721
11. Desai AA, Schilsky RL, Young A, Janisch L, Stadler WM, Vogelzang NJ, Cadden S, Wright JA, Ratain MJ (2005) A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol 16(6):958-965
12. Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A, Butler D, Charisse K, Dorkin R, Fan Y et al (2008) Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 105(33):11915-11920
13. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V et al (2005) Potent and persistent in vivo anti-HBV activity of chemically modifi ed siRNAs. Nat Biotechnol 23(8):1002-1007
14. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M et al (2006) RNAi-mediated gene silencing in non-human primates. Nature 441(7089):111-114
15. Davis ME (2009) The fi rst targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: From concept to clinic. Mol Pharm 6(3):659-668
16. Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, Langley RR et al (2008) Effect of interleukin-8 gene silencing with liposomeencapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 100(5):359-372
17. Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK (2005) Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65(15):6910-6918
18. Lara PN Jr, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S et al (2001) Prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to enrollment. J Clin Oncol 19(6):1728-1733
19. Tasciotti E, Liu X, Bhavane R, Plant K, Leonard AD, Price BK, Cheng MM, Decuzzi P, Tour JM, Robertson F et al (2008) Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol 3(3):151-157
20. Tanaka T, Godin B, Bhavane R, Nieves-Alicea R, Gu J, Liu X, Chiappini C, Fakhoury JR, Amra S, Ewing A, Li Q, Fidler IJ, Ferrari M (2010) In vivo evaluation of safety of nanoporous silicon carriers following single and multiple dose intravenous administrations in mice. Int J Pharm 402(1-2):190-197
21. Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, Han HD, Shahzad MM, Liu X, Bhavane R et al (2010) Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res 70(9):3687-3696